FROM CELL SYSTEMS
FROM CELL SYSTEMS
AnaBios primary human hepatocytes provide the most comprehensive metabolic activity for researchers studying liver function and drug metabolism. Our hepatocytes are carefully isolated and characterized to ensure excellent quality and consistency. AnaBios hepatocytes have demonstrated high viability and functionality, making them an ideal model for predicting drug metabolism and toxicity in humans.
Evaluation of the Utility of the Beta Human Liver Emulation System (BHLES) for CFSAN's RegulatoryToxicology program
The Center for Food Safety and Applied Nutrition collaborated with Emulate to assess the Beta Human Liver Emulation System (BHLES) for regulatory science. Using hepatotoxic and non-toxic compounds, the platform's performance was evaluated based on various parameters, including albumin secretion, urea, LDH release, nuclei number, mitochondrial membrane potential, and apoptosis.
LIF, A Mitogen for Choroidal Endothelial Cells, Protects the Choriocapillaris: Implications for Prevention of Geographic Atrophy
In this paper, leukemia inhibitory factor (LIF), typically known for inhibiting endothelial cell (EC) growth, was found to act as a mitogen for bovine choroidal EC (BCE) but inhibited bovine aortic EC (BAE) growth.
Three-Dimensional Human Liver-Chip Emulating Premetastatic Niche Formation by Breast Cancer-Derived Extracellular Vesicles
Breast cancer frequently metastasizes to the liver, posing a significant threat. A three-dimensional microfluidic human liver-on-a-chip model was developed to simulate the formation of a premetastatic niche and explore the role of breast cancer-derived extracellular vesicles (EVs) in liver metastasis. The study revealed that breast cancer-derived EVs activate liver sinusoidal endothelial cells (LSECs), triggering endothelial to mesenchymal transition and vessel barrier disruption.
Acceptance of Cell Systems cells as documented by placement of an order for Cell Systems products by an authorized representative constitutes knowledge, understanding, and binding acceptance of all binding restrictions on behalf of the recipient institution or enterprise.